IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Roger Cranwill who wrote (1002)	6/16/1997 7:51:00 PM
From: Pseudo Biologist	of 1762

Roger, just a small point to qualify the issue of "... hospitalization until radiation levels are acceptable ..." It appears some regulations have changed recently. See the info below and the associated caveats re. particular hospital, state regulations, etc. The September 23, 1996 issue of BioCentury contains an interesting "he says/she says" type of discussion with each company (IDEC & Coulter) making the case for their respective isotope (Yttrium vs. Iodine). Maybe this was discussed here eons ago. From Coulter's most recent 10K form "" Although patients to date have been kept in the hospital to monitor radiation levels for up to three days following the therapeutic dose, under recently enacted regulations of the Nuclear Regulatory Commission, the Company believes that the B-1 Therapy can be administered primarily on an outpatient basis. However, some hospitals may be required to administer the therapeutic dose on an inpatient basis under their own or under applicable state or local regulations.""

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next